Aktuellt
SENASTE
Redeye is impressed by the recruitment of Dr. Thomas Lönngren, former Head of EMA (2001 -2010), as the new Chairman. For a small biotech like Egetis, it is a clear validation of its strategic direction and the quality of the project portfolio. Also, we believe the new Chairman will add instrumental regulatory expertise, especially as Egetis is in late-stage clinical development.
LÄS MER
